Department and Institute of Physiology, College of Medicine, National Yang Ming Chiao Tung University, Taiwan.
Department of General Surgery, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan; Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Curr Opin Virol. 2021 Aug;49:194-202. doi: 10.1016/j.coviro.2021.06.006. Epub 2021 Jul 7.
Hepatitis B virus (HBV) chronically infects 257 million people and is one of the most important liver diseases worldwide. A unique feature of HBV infection in humans is that viral clearance heavily depends on the age at exposure. Recent studies demonstrated that the virus takes advantage of immature innate immunity, especially hepatic macrophages, and not-yet-stabilized gut microbiota in early life to establish a chronic infection. The liver contains resident and infiltrating myeloid cells involved in immune responses to pathogens. They influence both innate and adaptive sectors of the immune system and their interplay with HBV has only been noticed recently. Here, we discuss how interactions between gut microbiota and hepatic macrophages influence the outcomes of HBV infection. Understanding the underlying mechanism would pave the way for the treatment of chronic HBV infection.
乙型肝炎病毒 (HBV) 慢性感染 2.57 亿人,是全球最重要的肝脏疾病之一。HBV 感染在人类中的一个独特特征是病毒清除在很大程度上取决于感染时的年龄。最近的研究表明,病毒利用不成熟的固有免疫,特别是肝巨噬细胞,以及生命早期尚未稳定的肠道微生物群,来建立慢性感染。肝脏中含有参与对病原体免疫反应的常驻和浸润性髓样细胞。它们影响先天和适应性免疫系统的两个部分,而它们与 HBV 的相互作用直到最近才被注意到。在这里,我们讨论了肠道微生物群和肝巨噬细胞之间的相互作用如何影响 HBV 感染的结果。了解潜在的机制将为慢性 HBV 感染的治疗铺平道路。